Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Pfizer Inc.235 East 42nd Street, New York, NY 10017
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 5 ans
TBE SEROPERSISTENCE AFTER FIRST BOOSTER IN CHILDREN (FOLLOW-UP TO STUDY 700401)
The main purpose of this study is to assess the seropersistence at yearly intervals from approximately 3 years (38 months) to 10 years (118 months) after the first booster vaccination (as applicable) ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 5 ans
A LONG-TERM OPEN-LABEL EXTENSION STUDY OF LERSIVIRINE FOR THE TREATMENT OF HIV-1 INFECTION
To assess the long-term safety and efficacy of lersivirine in subjects who have completed treatment with lersivirine in the parent protocols.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 5 ans
This study is a non-drug follow up study to A3051123 for cardiac assessments after use of smoking cessation treatments
The primary objective of the CV safety assessment will be to characterize the cardiovascular safety profiles of varenicline and bupropion compared to placebo.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 5 ans
PHASE 1B OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066) IN TUMORS WITH GENETIC EVENTS INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK ) GENE LOCUS
Assess the safety of oral single-agent crizotinib administered to patients with advanced malignancy known to have an ALK genetic event and screen for efficacy in these patients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 5 ans
A PHASE 2 MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF 04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE ON STABLE DONEPEZIL THERAPY
The primary objective of this Protocol is to assess the efficacy of PF 04447943, relative to placebo, on a performance based measure of cognition in subjects with mild to moderate AD who are on stable...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 5 ans
PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP-690,550 COMPARED TO METHOTREXATE IN METHOTREXATE-NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS
1. To compare evidence of preservation of joint structure after administration of CP-690,550 in doses of 5 mg BID and 10 mg BID versus MTX alone in MTX-naïve patients with active RA, as measured by ch...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
4
5
6
7
8
9
10
11
12
13